Limits...
Aggressive multimodal therapy may prolong disease-free survival in recurrent primary retroperitoneal embryonal carcinoma.

Straka M, Manasek V, Stursa M, Andelova R - Int J Surg Case Rep (2015)

Bottom Line: The patient is currently disease-free at 34 months.Aggressively treated metastatic recurrent disease does not preclude prolonged survival.Despite a generally poor prognosis, repeated complex oncosurgical therapy for retroperitoneal extragonadal tumours may be worthwhile.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Comprehensive Cancer Centre and AGEL Research and Training Institute, Novy Jicin Hospital, Purkynova 2138-16, 741 01 Novy Jicin Czech Republic. Electronic address: tulakmato@gmail.com.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemistry staining. (A) High proliferation activity Ki 67 stain (200×). (B) Positivity for CD 30 stain (400×). (C) Positivity for PLAP stain (400×). (D) Positivity for CK AE 1/3 (400×).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4430178&req=5

fig0015: Immunohistochemistry staining. (A) High proliferation activity Ki 67 stain (200×). (B) Positivity for CD 30 stain (400×). (C) Positivity for PLAP stain (400×). (D) Positivity for CK AE 1/3 (400×).

Mentions: A 42-year-old, obese (BMI 34.4 kg m−2), Caucasian male presented with left sided obstructive nephropathy due to a retroperitoneal primary in 10/2007. Retroperitoneal lymphadenopathy on abdominal ultrasonography (USG) and computed tomography (CT) raised suspicion of lymphoma (Fig. 1). After ureteral stent placement laparoscopic biopsy was performed. The histopathology revealed a germinal tumour formed predominantly by embryonal carcinoma cells (99%) and a small proportion of choriocarcinoma cells (1%) (Fig. 2). Immunohistochemistry staining was positive for CD30, PLAP and ßHCG (Fig. 3). Bilateral open testes biopsy proved negative. Based on the CT, MRI, histopathology and tumour marker level, the disease was staged as “intermediate risk” according to the International Germ Cell Cancer Collaborative Group (IGCCCG) criteria. The case was presented at a multidisciplinary team conference for consensus decision-making on multimodal treatment.


Aggressive multimodal therapy may prolong disease-free survival in recurrent primary retroperitoneal embryonal carcinoma.

Straka M, Manasek V, Stursa M, Andelova R - Int J Surg Case Rep (2015)

Immunohistochemistry staining. (A) High proliferation activity Ki 67 stain (200×). (B) Positivity for CD 30 stain (400×). (C) Positivity for PLAP stain (400×). (D) Positivity for CK AE 1/3 (400×).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4430178&req=5

fig0015: Immunohistochemistry staining. (A) High proliferation activity Ki 67 stain (200×). (B) Positivity for CD 30 stain (400×). (C) Positivity for PLAP stain (400×). (D) Positivity for CK AE 1/3 (400×).
Mentions: A 42-year-old, obese (BMI 34.4 kg m−2), Caucasian male presented with left sided obstructive nephropathy due to a retroperitoneal primary in 10/2007. Retroperitoneal lymphadenopathy on abdominal ultrasonography (USG) and computed tomography (CT) raised suspicion of lymphoma (Fig. 1). After ureteral stent placement laparoscopic biopsy was performed. The histopathology revealed a germinal tumour formed predominantly by embryonal carcinoma cells (99%) and a small proportion of choriocarcinoma cells (1%) (Fig. 2). Immunohistochemistry staining was positive for CD30, PLAP and ßHCG (Fig. 3). Bilateral open testes biopsy proved negative. Based on the CT, MRI, histopathology and tumour marker level, the disease was staged as “intermediate risk” according to the International Germ Cell Cancer Collaborative Group (IGCCCG) criteria. The case was presented at a multidisciplinary team conference for consensus decision-making on multimodal treatment.

Bottom Line: The patient is currently disease-free at 34 months.Aggressively treated metastatic recurrent disease does not preclude prolonged survival.Despite a generally poor prognosis, repeated complex oncosurgical therapy for retroperitoneal extragonadal tumours may be worthwhile.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Comprehensive Cancer Centre and AGEL Research and Training Institute, Novy Jicin Hospital, Purkynova 2138-16, 741 01 Novy Jicin Czech Republic. Electronic address: tulakmato@gmail.com.

No MeSH data available.


Related in: MedlinePlus